In connection with this sale, Thomas has agreed to voluntarily disgorge the short swing profits realized from this transaction and a prior purchase of 1,086 units during the company's rights offering earlier this year. Thomas has proactively contacted Pulse Biosciences (NASDAQ:PLSE) to arrange for the payment of this disgorgement. InvestingPro data shows the company maintains strong liquidity with a current ratio of 11.93, while trading at a notable price-to-book ratio of 13.98. Discover more insights about PLSE and access the comprehensive Pro Research Report, available exclusively with an InvestingPro subscription. InvestingPro data shows the company maintains strong liquidity with a current ratio of 11.93, while trading at a notable price-to-book ratio of 13.98. Discover more insights about PLSE and access the comprehensive Pro Research Report, available exclusively with an InvestingPro subscription.
In connection with this sale, Thomas has agreed to voluntarily disgorge the short swing profits realized from this transaction and a prior purchase of 1,086 units during the company's rights offering earlier this year. Thomas has proactively contacted Pulse Biosciences to arrange for the payment of this disgorgement.
In other recent news, Pulse Biosciences has announced a series of significant changes. The company disclosed the departure of its President and CEO, Mr. Burke T. Barrett, who also stepped down from the Board of Directors. In the interim, the roles of principal executive and principal financial officers will be assumed by Kevin P. Danahy, the Chief Commercial Officer, and Darrin R. Uecker, the Chief Technology Officer, respectively.
On the financial front, despite recording a GAAP net loss of $12.7 million for Q3 2024, Pulse Biosciences raised $60 million through a rights offering, ending the quarter with $79 million in cash and cash equivalents. Major stockholder and Co-Chairman Robert W. Duggan is considering substantial market purchases of the company's common stock, signaling his potential increased investment.
In terms of medical advancements, Pulse Biosciences reported promising preliminary results from a feasibility study on its Nanosecond Pulsed Field Ablation (nano-PFA) technology. The study indicated the technology's potential in reducing benign thyroid nodules and providing symptomatic relief. The company also treated its first Atrial Fibrillation patients in Europe using the nano-PFA Cardiac Surgical System, which has received U.S. FDA breakthrough device designation. These are recent developments in the company's journey.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.